Cargando…
Vitamin D and methylarginines in chronic kidney disease (CKD)
BACKGROUND: Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627906/ https://www.ncbi.nlm.nih.gov/pubmed/28976989 http://dx.doi.org/10.1371/journal.pone.0185449 |
_version_ | 1783268794947338240 |
---|---|
author | Torino, Claudia Pizzini, Patrizia Cutrupi, Sebastiano Tripepi, Rocco Tripepi, Giovanni Mallamaci, Francesca Zoccali, Carmine |
author_facet | Torino, Claudia Pizzini, Patrizia Cutrupi, Sebastiano Tripepi, Rocco Tripepi, Giovanni Mallamaci, Francesca Zoccali, Carmine |
author_sort | Torino, Claudia |
collection | PubMed |
description | BACKGROUND: Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug. METHODS: In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD. RESULTS: Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70–0.81), 12 week 0.72 μMol/L (95%CI: 0.66–0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70–0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66–0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82–1.00), 12 week 0.94 μMol/L (95%CI: 0.82–0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82–1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88–1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments. CONCLUSIONS: Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3–4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism. |
format | Online Article Text |
id | pubmed-5627906 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-56279062017-10-20 Vitamin D and methylarginines in chronic kidney disease (CKD) Torino, Claudia Pizzini, Patrizia Cutrupi, Sebastiano Tripepi, Rocco Tripepi, Giovanni Mallamaci, Francesca Zoccali, Carmine PLoS One Research Article BACKGROUND: Vitamin D associates with the plasma concentration of the endogenous inhibitor of the nitric oxide system asymmetric dimethyl arginine (ADMA) and cross-sectional studies in CKD patients treated with the vitamin D receptor activator paricalcitol show that plasma ADMA is substantially less than in those not receiving this drug. METHODS: In the frame of a randomized, double-blind, placebo controlled trial, the Paracalcitol and ENdothelial fuNction in chronic kidneY disease (PENNY), we investigated whether vitamin D receptor activation by paricalcitol (2 μg/day x 12 weeks) affects the plasma concentration of ADMA and symmetric dimethyl arginine (SDMA) in 88 patients with stage 3 to 4 CKD. RESULTS: Paricalcitol produced the expected small rise in serum calcium and phosphate and a marked PTH suppression. However, ADMA [Paricalcitol: baseline 0.75 μMol/L (95%CI: 0.70–0.81), 12 week 0.72 μMol/L (95%CI: 0.66–0.78); Placebo: baseline 0.75 μMol/L (95%CI: 0.70–0.90) 12 weeks 0.70 μMol/L (95%CI: 0.66–0.74)] and SDMA [Paricalcitol: baseline 0.91 μMol/L (95%CI: 0.82–1.00), 12 week 0.94 μMol/L (95%CI: 0.82–0.1.06); Placebo: baseline 0.91 μMol/L (95%CI: 0.82–1.06) 12 weeks 0.99 μMol/L (95%CI: 0.88–1.10)] remained unchanged during the trial and 2 weeks after stopping these treatments. CONCLUSIONS: Paricalcitol does not modify plasma ADMA and SDMA in patients with stage 3–4 CKD. The apparent beneficial effects of paricalcitol on ADMA registered in cross-sectional studies is likely attributable to confounding by indication rather than to a true effect of this drug on ADMA metabolism. Public Library of Science 2017-10-04 /pmc/articles/PMC5627906/ /pubmed/28976989 http://dx.doi.org/10.1371/journal.pone.0185449 Text en © 2017 Torino et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Torino, Claudia Pizzini, Patrizia Cutrupi, Sebastiano Tripepi, Rocco Tripepi, Giovanni Mallamaci, Francesca Zoccali, Carmine Vitamin D and methylarginines in chronic kidney disease (CKD) |
title | Vitamin D and methylarginines in chronic kidney disease (CKD) |
title_full | Vitamin D and methylarginines in chronic kidney disease (CKD) |
title_fullStr | Vitamin D and methylarginines in chronic kidney disease (CKD) |
title_full_unstemmed | Vitamin D and methylarginines in chronic kidney disease (CKD) |
title_short | Vitamin D and methylarginines in chronic kidney disease (CKD) |
title_sort | vitamin d and methylarginines in chronic kidney disease (ckd) |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627906/ https://www.ncbi.nlm.nih.gov/pubmed/28976989 http://dx.doi.org/10.1371/journal.pone.0185449 |
work_keys_str_mv | AT torinoclaudia vitamindandmethylargininesinchronickidneydiseaseckd AT pizzinipatrizia vitamindandmethylargininesinchronickidneydiseaseckd AT cutrupisebastiano vitamindandmethylargininesinchronickidneydiseaseckd AT tripepirocco vitamindandmethylargininesinchronickidneydiseaseckd AT tripepigiovanni vitamindandmethylargininesinchronickidneydiseaseckd AT mallamacifrancesca vitamindandmethylargininesinchronickidneydiseaseckd AT zoccalicarmine vitamindandmethylargininesinchronickidneydiseaseckd |